Neurofilament light chain is the closest thing we have to a universal neurodegeneration biomarker—but it has a blind spot

NfL levels rise in ALS, Parkinsons, Alzheimers, and MS. It tracks disease progression and predicts outcomes. But here is the problem: it tells you that neurons are dying, not whether your treatment is working.